SCHEMBL1383463

SCHEMBL1383463

O=C(O)C1=CCN(c2ccccn2)C=C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALKBH2 Q6NS38 1/20 0.41
EGLN1 Q9GZT9 1/20 0.41
ALDH1A1 P00352 9/20 0.41
KDM4E B2RXH2 6/20 0.41
L3MBTL1 Q9Y468 2/20 0.39
LMNA P02545 2/20 0.39
NAPRT Q6XQN6 1/20 0.39
P4HTM Q9NXG6 1/20 0.39
HPGD P15428 2/20 0.38
HSD17B10 Q99714 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
RECQL P46063 1/20 0.38
ADRB2 P07550 1/20 0.38
MAPK1 P28482 1/20 0.37
SLC6A7 Q99884 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HTR1A P08908 1/20 0.36
BCHE P06276 1/20 0.36
ACHE P22303 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1370074 0.87 PLK4 (0.38) ALKBH2EGLN1ALDH1A1KDM4EHPGD
SCHEMBL2513039 0.80 HPGD (0.47) ALDH1A1KDM4ELMNAHPGDHSD17B10
SCHEMBL28013191 0.79 KDM4E (0.44) ALKBH2EGLN1ALDH1A1KDM4EL3MBTL1
SCHEMBL390365 0.78 PLD1 (0.38) ALDH1A1KDM4ESMN1; SMN2CRBN
SCHEMBL27770862 0.78 POLB (0.33) ALKBH2ALDH1A1KDM4ENAPRTHPGD
SCHEMBL28547827 0.75 SMN1; SMN2 (0.42) ALDH1A1KDM4ESMN1; SMN2CRBN
SCHEMBL28545863 0.70 HTT (0.43) ALDH1A1KDM4EL3MBTL1LMNAHPGD
SCHEMBL28138880 0.68 NOTUM (0.37) ALDH1A1KDM4EL3MBTL1HPGDRECQL
SCHEMBL8159568 0.67 ALKBH2 (0.43) ALKBH2EGLN1ALDH1A1KDM4EL3MBTL1
SCHEMBL2096767 0.66 PLD1 (0.44) ALDH1A1KDM4ELMNAHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4790704-B2 2011-10-12 JP claimed
EP-2378878-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE Via Pharmaceuticals, Inc. (US) 2011-10-26 EP disclosed
US-7816364-B2 GRP119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto ARENA PHARMACEUTICALS, INC. (US) 2010-10-19 US disclosed
US-20100190824-A1 Novel Substituted Piperidones as HSP Inducers TORRENT PHARMACEUTICALS LTD. (IN) 2010-07-29 US disclosed
US-20100190750-A1 GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto ARENA PHARMACEUTICALS, INC. (US) 2010-07-29 US disclosed
US-20090270422-A1 GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto ARENA PHARMACEUTICALS, INC. 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190750-A1 GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto GPR119, GLP1R, GPR4 ALKBH2 3232/4885EGLN1 2575/4885ALDH1A1 2608/4885
US-20090270422-A1 GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto GPR119, GLP1R, GPR4 ALKBH2 3232/4885EGLN1 2575/4885ALDH1A1 2608/4885
US-20100190824-A1 Novel Substituted Piperidones as HSP Inducers HSF1, HSPA4, HSPA5 ALKBH2 3921/4885EGLN1 3458/4885ALDH1A1 541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.